Disciplined Growth Investors Inc. MN lessened its position in shares of Medidata Solutions Inc (NASDAQ:MDSO) by 3.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 723,155 shares of the company’s stock after selling 24,994 shares during the quarter. Disciplined Growth Investors Inc. MN owned about 1.24% of Medidata Solutions worth $56,449,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Zions Bancorporation acquired a new stake in Medidata Solutions during the 3rd quarter worth approximately $256,000. Jane Street Group LLC lifted its position in Medidata Solutions by 112.8% during the 3rd quarter. Jane Street Group LLC now owns 9,505 shares of the company’s stock worth $742,000 after acquiring an additional 5,038 shares during the period. AMP Capital Investors Ltd acquired a new stake in Medidata Solutions during the 3rd quarter worth approximately $2,194,000. Polen Capital Management LLC acquired a new stake in Medidata Solutions during the 3rd quarter worth approximately $205,000. Finally, Sirios Capital Management L P lifted its position in Medidata Solutions by 35.3% during the 3rd quarter. Sirios Capital Management L P now owns 51,077 shares of the company’s stock worth $3,987,000 after acquiring an additional 13,322 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.
A number of analysts have weighed in on MDSO shares. Jefferies Group reaffirmed a “hold” rating and set a $78.00 price objective on shares of Medidata Solutions in a research report on Tuesday, August 22nd. KeyCorp reaffirmed a “buy” rating and set a $86.00 price objective on shares of Medidata Solutions in a research report on Sunday, September 17th. Royal Bank Of Canada started coverage on Medidata Solutions in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $82.00 price objective for the company. Zacks Investment Research raised Medidata Solutions from a “sell” rating to a “hold” rating in a research report on Wednesday, September 20th. Finally, Wells Fargo & Company decreased their price objective on Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a research report on Friday, October 27th. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $84.54.
In other news, EVP Michael I. Otner sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $70.88, for a total value of $708,800.00. Following the completion of the sale, the executive vice president now directly owns 80,674 shares of the company’s stock, valued at approximately $5,718,173.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Tarek Sherif sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $68.76, for a total value of $13,752,000.00. The disclosure for this sale can be found here. Insiders sold a total of 237,010 shares of company stock valued at $16,305,136 over the last three months. Insiders own 5.80% of the company’s stock.
Shares of Medidata Solutions Inc (NASDAQ MDSO) opened at $66.23 on Monday. The company has a quick ratio of 3.37, a current ratio of 1.29 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $3,871.87, a P/E ratio of 79.80, a PEG ratio of 4.12 and a beta of 1.69. Medidata Solutions Inc has a 1-year low of $47.77 and a 1-year high of $85.92.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings results on Thursday, October 26th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.31 by $0.02. The business had revenue of $140.08 million during the quarter, compared to analysts’ expectations of $141.27 million. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period last year, the firm earned $0.28 EPS. sell-side analysts anticipate that Medidata Solutions Inc will post 0.77 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/11/disciplined-growth-investors-inc-mn-reduces-position-in-medidata-solutions-inc-mdso.html.
Medidata Solutions Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.